These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. [New results in the management of hypercholesterolemia]. Sármán B Orv Hetil; 2005 Sep; 146(39):1999-2004. PubMed ID: 16265867 [TBL] [Abstract][Full Text] [Related]
8. The primary target. Taking aim at LDL levels to prevent cardiovascular disease. Mason CM Adv Nurse Pract; 2007 Dec; 15(12):55-8. PubMed ID: 20014676 [No Abstract] [Full Text] [Related]
9. Altering the pathophysiology of atherosclerosis: the multidimensional role of statins. Clearfield MB J Am Osteopath Assoc; 2010 Apr; 110(4 Suppl 4):S2-6. PubMed ID: 20453192 [TBL] [Abstract][Full Text] [Related]
10. [Primary and secondary prevention of coronary disease by statins]. Ferrières J Ann Cardiol Angeiol (Paris); 1999 Feb; 48(2):128-36. PubMed ID: 12555337 [TBL] [Abstract][Full Text] [Related]
11. Statin therapy in primary prevention: new insights regarding women and the elderly. Harrington C; Horne A; Hasan RK; Blumenthal RS Am J Cardiol; 2010 Nov; 106(9):1357-9. PubMed ID: 21029838 [No Abstract] [Full Text] [Related]
12. The JUPITER Trial: responding to the critics. Ridker PM; Glynn RJ Am J Cardiol; 2010 Nov; 106(9):1351-6. PubMed ID: 21029837 [No Abstract] [Full Text] [Related]
13. [Hyperlipidemia: decreasing lipid values and effects of statins]. Mathes P Z Kardiol; 2002; 91 Suppl 2():25-9. PubMed ID: 12436762 [No Abstract] [Full Text] [Related]
14. Biomarkers and surrogate endpoints in cardiovascular therapeutics research: under scrutiny following results of the ENHANCE Study. Pauriah M; Struthers AD; Lang CC Cardiovasc Ther; 2008; 26(2):85-8. PubMed ID: 18485130 [No Abstract] [Full Text] [Related]
15. Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk. Stewart RA Future Cardiol; 2009 May; 5(3):231-6. PubMed ID: 19656039 [TBL] [Abstract][Full Text] [Related]
16. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ; J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046 [TBL] [Abstract][Full Text] [Related]
17. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ; Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292 [TBL] [Abstract][Full Text] [Related]
18. [JUPITER can yield paradigmatic shift in the prevention of cardiovascular disease. Focus on inflammation as a risk factor]. Olsson AG Lakartidningen; 2009 May 20-Jun 2; 106(21-22):1471-5. PubMed ID: 19579435 [No Abstract] [Full Text] [Related]
19. Towards consistency between guidelines and policy: lipid management--2005. Tonkin AM Heart Lung Circ; 2005 Dec; 14(4):237-8. PubMed ID: 16360991 [No Abstract] [Full Text] [Related]
20. Updated guidelines support even lower cholesterol levels for at-risk patients. Levenson D Rep Med Guidel Outcomes Res; 2004 Aug; 15(15):1, 6-7. PubMed ID: 15320342 [No Abstract] [Full Text] [Related] [Next] [New Search]